- Home
- VYNE
as 02-03-2025 4:00pm EST
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 41.9M | IPO Year: | 2018 |
| Target Price: | $6.88 | AVG Volume (30 days): | 129.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.57 - $4.30 | Next Earning Date: | 02-27-2025 |
| Revenue: | $493,000 | Revenue Growth: | 39.27% |
| Revenue Growth (this year): | 28.3% | Revenue Growth (next year): | -53.12% |
Stock Insider Trading Activity of VYNE Therapeutics Inc. (VYNE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LEPORE PATRICK G | VYNE | Director | Jan 15 '25 | Buy | $2.92 | 15,000 | $43,800.00 | 51,472 |
Latest VYNE Therapeutics Inc. News
VYNE Breaking Stock News: Dive into VYNE Ticker-Specific Updates for Smart Investing
Argus Research
19 days ago
Daily – Vickers Top Buyers & Sellers for 01/17/2025
GlobeNewswire
a month ago
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo
Simply Wall St.
a month ago
US Penny Stocks To Watch In December 2024
TipRanks
a month ago
H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data
GlobeNewswire
a month ago
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
TipRanks
3 months ago
VYNE Therapeutics initiated with a Buy at BTIG on I&I potential
Simply Wall St.
3 months ago
VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GlobeNewswire
3 months ago
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Compare VYNE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VYNE VYNE Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.